The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.

IF 5.7 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-09-10 DOI:10.1111/dom.70081

Aidi Liu, Yumeng Shao, Jiayin Chen, Carmen S Ng, Yanyan Wu, Xuechen Xiong, Cindy L K Lam, Eric Y F Wan, Jianchao Quan

{"title":"The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.","authors":"Aidi Liu, Yumeng Shao, Jiayin Chen, Carmen S Ng, Yanyan Wu, Xuechen Xiong, Cindy L K Lam, Eric Y F Wan, Jianchao Quan","doi":"10.1111/dom.70081","DOIUrl":null,"url":null,"abstract":"Aim: To estimate the healthcare and economic burden associated with improved risk factor control for people with type 2 diabetes in Hong Kong over 10 years.Materials and methods: We obtained population-based data from electronic healthcare records of the Hong Kong Hospital Authority. Risk factor targets were defined by American Diabetes Association guidelines. We applied a validated patient-level diabetes outcomes model (Chinese Hong Kong Integrated Modelling and Evaluation) to estimate the health and economic outcomes for all individuals with type 2 diabetes (n = 526 672) in Hong Kong in 2021. Immediate risk factor control was compared to baseline over 10 years. Costs were estimated from a healthcare provider perspective.Results: Most people (84.9%) failed to achieve optimal combined risk factors control (glycated haemoglobin, blood pressure and low-density lipoprotein-cholesterol) at baseline. Combined control was associated with population-level increases in quality-adjusted life-years (QALYs) of 17 605 and healthcare cost savings of US$ 106.7 million over 10 years. Glycaemic control solely yielded the greatest QALY increases and had the highest cost savings (US$ 29.0 million) over 10 years.Conclusions: The substantial population health and economic burden of inadequate risk factor control for individuals with diabetes in Hong Kong can potentially be mitigated through enhanced adherence, highlighting the need for effective and intensive interventions.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.70081","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To estimate the healthcare and economic burden associated with improved risk factor control for people with type 2 diabetes in Hong Kong over 10 years.

Materials and methods: We obtained population-based data from electronic healthcare records of the Hong Kong Hospital Authority. Risk factor targets were defined by American Diabetes Association guidelines. We applied a validated patient-level diabetes outcomes model (Chinese Hong Kong Integrated Modelling and Evaluation) to estimate the health and economic outcomes for all individuals with type 2 diabetes (n = 526 672) in Hong Kong in 2021. Immediate risk factor control was compared to baseline over 10 years. Costs were estimated from a healthcare provider perspective.

Results: Most people (84.9%) failed to achieve optimal combined risk factors control (glycated haemoglobin, blood pressure and low-density lipoprotein-cholesterol) at baseline. Combined control was associated with population-level increases in quality-adjusted life-years (QALYs) of 17 605 and healthcare cost savings of US$ 106.7 million over 10 years. Glycaemic control solely yielded the greatest QALY increases and had the highest cost savings (US$ 29.0 million) over 10 years.

Conclusions: The substantial population health and economic burden of inadequate risk factor control for individuals with diabetes in Hong Kong can potentially be mitigated through enhanced adherence, highlighting the need for effective and intensive interventions.

查看原文本刊更多论文

香港2型糖尿病风险因素控制不足所带来的医疗及经济负担：一项以人口为基础的模型研究

目的：评估香港2型糖尿病患者在改善风险因素控制后10年内的医疗保健和经济负担。材料和方法：我们从香港医院管理局的电子医疗记录中获得基于人群的数据。风险因素指标由美国糖尿病协会指南确定。我们应用了一个经过验证的患者水平的糖尿病结局模型（中国香港综合模型和评估）来估计2021年香港所有2型糖尿病患者（n = 526 672）的健康和经济结局。将即时风险因素控制与10年来的基线进行比较。从医疗保健提供者的角度估计成本。结果：大多数人（84.9%）在基线时未能达到最佳的综合危险因素控制（糖化血红蛋白、血压和低密度脂蛋白-胆固醇）。综合控制与人口水平的质量调整生命年（QALYs）增加17605年和10年内医疗保健费用节省1.067亿美元有关。血糖控制单独产生最大的QALY增加，并在10年内节省了最高的成本（2900万美元）。结论：香港糖尿病患者风险因素控制不足所带来的巨大人口健康和经济负担可以通过加强依从性来减轻，这突出了有效和强化干预的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.